Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Functional characterization of novel non-coding RNA transcripts in bladder cancer

Funder: Canadian Institutes of Health Research

Funding period
CAD 22 K
USD 17 K
Funding amount
Abstract
Bladder cancer is one of the most common types of cancer in Canada. Various subtypes of bladder cancer respond differently to treatment, and recurrences are frequently observed. Under the microscope, many bladder cancers that are invasive look the same as ones that are more benign, even though may have very different genetic characteristics. There are currently no targeted therapies for bladder cancer, and the primary treatment is to surgically remove the bladder, an operation which significantly impacts the patient's quality of life, and is often times unnecessary. Thus, it would be imperative to know whether specific cancers could be targeted for death without bladder removal. Working with world leading clinicians and scientists, we have used cutting edge genetic tools called RNAseq and DyNeMo to analyze specific genetic characteristics of aggressive types of bladder cancer from frozen patient samples. Preliminary results point to very specific cell signalling pathways which can drive the migration and growth of bladder tumours. We also identified very unique intracellular biological molecules called 'enhancer RNAs' that can be potential candidates for targeted therapy as they are specific to each type of cancer. Initial results aimed at depleting these molecules in bladder cancer cell lines have yielded encouraging results, highlighted by an increase in cancer cell death. Continued work will aim to characterize the signalling pathways that make the bladder cancers more invasive and also to characterize the enhancer RNAs for the specific and targeted treatment of various bladder cancers. Ultimately, we hope that using our tools we will create a diagnostic genetic signature of aggressive bladder cancers, so that a patient's initial surgical sample can be used in a test in the clinic to determine whether a patient requires surgery or not, and whether they may be a candidate for a targeted treatment.
Similar projects All >
Sorted by: Start Date
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Characterization of Nectin-4 expression in molecular subtypes of urothelial cancer and mechanisms of resistance to enfortumab vedotin

Bladder Cancer Advocacy Network to Carissa Ellen Chu

USD 1,700
2020 - 2020
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2020 - 2021
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Genetics

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • HRCS RAC

    4.1 Discovery and preclinical testing of markers and technologies

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Basic Science